Pharmacodynamic optimization of beta-lactams in the patient care setting (Q37169843)

18 August 2017

2 references

23 March 2019

7 November 2019

Pharmacodynamic optimization of beta-lactams in the patient care setting (English)

1 reference

gram-negative bacterial infection

18 August 2017

2 references

23 March 2019

7 November 2019

1 reference

7 November 2019

1 reference

1 reference

David P Nicolau

1

1 reference

18 August 2017

21 May 2008

3 references

18 August 2017

23 March 2019

7 November 2019

3 references

18 August 2017

23 March 2019

7 November 2019

12 Suppl 4

1 reference

18 August 2017

S2

1 reference

https://scigraph.springernature.com/pub.10.1186/cc6818

18 August 2017

0 references

cites work

The Combined Use of Penicillin and Heparin in the Treatment of Subacute Bacterial Endocarditis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Importance of nondrug costs of intravenous antibiotic therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

The pharmacology of meropenem, a new carbapenem antibiotic

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Continuous infusion versus intermittent administration of meropenem in critically ill patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391264

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps

3 September 2018

1 reference

12 December 2020

Prevention of resistance: a goal for dose selection for antimicrobial agents

1 reference

12 December 2020

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy

1 reference

12 December 2020

Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals

1 reference

12 December 2020

The effect of anticoagulants on the penicillin therapy and the pathologic lesions of subacute bacterial endocarditis

1 reference

12 December 2020

Identifiers

DOI

10.1186/CC6818

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

PMCID

2391264